Contact:Martin ForrestVP Corporate Communications and Investor Relations510-450-3528
EMERYVILLE, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will present at the Stifel 2016 Healthcare Conference in New York on Tuesday, November 15 th 2016 at 9:30 a.m. Eastern Time. The presentation will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events.cfm and available for approximately two weeks. About Adamas Pharmaceuticals, Inc. Adamas is a pharmaceutical company that is developing new medicines to improve the daily lives of those affected by chronic neurologic disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. Adamas has pioneered a platform based on an understanding of time-dependent biologic effects of disease activity and drug response to potentially achieve symptomatic relief without additional tolerability issues. We have developed a portfolio of Chrono-Synchronous Therapies (CSTs) to address chronic neurologic disorders. In addition to ADS-5102, we are investigating ADS-4101 for the improved control of epileptic seizures. Additionally through our license agreement with Forest Laboratories Holding Ltd. (a wholly owned subsidiary of Allergan plc), we are eligible to receive royalties on sales of NAMENDA XR ® and NAMZARIC ® beginning in June of 2018 and May of 2020, respectively. For more information, please visit www.adamaspharma.com. NAMENDA XR ® and NAMZARIC ® are registered trademarks of Merz Pharma GmbH & Co. KGaA.